New Investment in AIRNA

LEI: 549300Q7EXQQH6KF7Z84

03 April 2025

RTW Biotech Opportunities Ltd

New Investment in AIRNA

RTW Biotech Opportunities Ltd (the "Company"), the London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to note the announcement by new portfolio company, AIRNA, of the closing of its oversubscribed $155 million Series B financing round.

AIRNA is a biotech company harnessing advances in genetics to develop RNA-editing medicines to transform the lives of patients. It is advancing a robust pipeline of therapeutic candidates that are designed to provide functional cures for severe or chronic diseases by repairing harmful genetic variants or introducing beneficial variants to promote optimal health.

AIRNA will use the proceeds of the fund raising to advance its lead RNA-editing product candidate (AIR-001) for Alpha-1 antitrypsin deficiency (AATD), a condition which results in lung and liver disease, into a Phase 1/2 clinical trial, in addition to developing a pipeline of novel RNA-editing medicines for cardiometabolic and other diseases.

Roderick Wong, Managing Partner and CIO at RTW Investments, LP said, "We are thrilled to support AIRNA in its mission to develop a new class of genetic medicines. Their pioneering work in precise RNA editing holds the promise to significantly advance therapeutic options for patients with AATD and other diseases. We believe AIRNA's lead program has best-in-class potential for AATD and look forward to collaborating with AIRNA and witnessing the impact of their approach on patient care."

The full text of the announcement can be read at https://airna.com.

Enquiries:

About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd for more information.

***********

The information in this announcement may include forward-looking statements, which are based on the current expectations and projections about future events, and in certain cases can be identified by the use of terms such as "may", "will", "should", "expect", "anticipate", "project", "estimate", "intend", "continue", "target", "believe" (or the negatives thereon) or other variations thereon or comparable terminology. These forward-looking statements, as well as those included in any related materials, are subject to risks, uncertainties and assumptions about the Company and/or its underlying investments, including, among other things, the development of the applicable entity's business, trends in its operating industry, expected use of financing proceeds and future capital expenditures and acquisitions. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not occur.

The information contained in this announcement is given at the date of its publication (unless otherwise marked). No reliance may be placed for any purpose whatsoever on the information or opinions contained in this announcement or on its completeness, accuracy or fairness.

***********